Rhythm Biotherapeutics Inc.

We are pleased to share our new look at www.rthm.bio! Recommendations and props to Carolyn (Vermeulen) Olauson for her great work... and being great to work with.

Meet Darryl Davis at #RESIJPM. Learn more at our booth, or by speaking with our friends at Capital BioVentures and OBIO: Julia Pomoransky (Rintoul), Jose L. RodriguezJ and Jack Lee.

Thank you Ottawa Business Journal and Dave Sali! https://lnkd.in/gTq2g2c6 University of Ottawa Heart Institute, Capital BioVentures, OBIO, Invest Ottawa

New initiative to eliminate postoperative atrial fibrillation November 12, 2024 Ottawa, November 12, 2024 - The University of Ottawa Heart Institute (UOHI) has played a pivotal role toward preventing a serious complication following open-chest surgery by helping launch Rhythm Biotherapeutics Inc., a pre-clinical startup company pioneering novel biologic therapies for patients with heart disease. The initiative aims to bring the UOHI’s groundbreaking therapeutic from bench to bedside.... “Rhythm Biotherapeutics is uniquely positioned to translate this cutting-edge research into transformative therapy,” said Dr. Darryl Davis, founder and CEO at Rhythm Biotherapeutics and an electrophysiologist and scientist at the University of Ottawa Heart Institute. “Our mission is to prevent and cure atrial fibrillation, starting with our exosome therapy for postoperative atrial fibrillation, a complication that affects so many patients after cardiac surgery.”... https://lnkd.in/e8gN2N3q University of Ottawa Heart Institute, Darryl Davis

We are pleased to announce that Noreen Ahmed, PhD will present "Human extracellular vesicles prevent inflammation in a human model of postoperative atrial fibrillation" tomorrow in Houston at the American Association of Extracellular Vesicles' AAEV2024 conference. Darryl Davis, University of Ottawa Heart Institute, Capital BioVentures, OBIO, Invest Ottawa, Intellectual Property Ontario (IPON), Mike Weider, Adim De, Chantal Martin, PhD, Jeff Smirle, Julia Pomoransky (Rintoul), Maura Campbell, Dane Bedward, Patrick Bedford, Stephen Fanjoy, FCMC,

Dr. Darryl Davis is pleased to be presenting this week in Australia at the Asia Pacific Heart Rhythm Society 2024 conference. He will be delivering two talks: "Extracellular Vesicle Therapy for Atrial Fibrillation" in the Emerging Therapies for Arrhythmias session and "Arrhythmias in a Model of Chronic Inflammation" in the Mechanisms of Arrhythmias session.

We are excited to announce that Rhythm Biotherapeutics is a finalist at Capital Angel Network MASHUP24 on September 17th. We look forward to meeting with the other finalists and the great community of startup investors and supporters here in Ottawa. Learn more here: https://lnkd.in/gYt_t9mS Please join us and get your tickets here: https://lnkd.in/ezJTci5M

We are excited to announce that Rhythm Biotherapeutics is a finalist at Capital Angel Network MASHUP24 on September 17th. We look forward to meeting with the other finalists and the great community of startup investors and supporters here in Ottawa. Learn more here: https://lnkd.in/gYt_t9mS Please join us and get your tickets here: https://lnkd.in/ezJTci5M

RNA and the emerging potential of bio-inspired molecules in cardiovascular disease therapies, by Noreen Ahmed, PhD, Darryl Davis European Heart Journal 13 June 2024 Open access https://lnkd.in/eri-A7_J

Darryl Davis is pleased to be presenting, June 15th, at the International Forum on Cardiovascular Disease, Stem Cells and Tissue Engineering in Taiyuan China: Exosome-Based Prevention of Postoperative Atrial Fibrillation The prevention of atrial fibrillation (AF) following open-chest surgery remains a significant clinical challenge, impacting 20-40% of cardiac surgery patients and leading to increased morbidity and mortality. This presentation explores the innovative use of extracellular vesicle (EV) therapy derived from heart cells as a promising intervention for this condition. EVs have demonstrated the ability to reduce inflammation and fibrosis, key factors in the pathogenesis of AF, by modulating the cardiac immune response and preventing the activation of atrial fibroblasts. In vivo studies show that a single dose of EVs administered during surgery can significantly mitigate postoperative AF, potentially revolutionizing postoperative care and improving patient outcomes.